

Saskatchewan Immunization Manual Amendments **May 2015**

Instructions: Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **May 2015**.

Chapter 1 – Introduction

- P. 1 (April 2012)
 - First paragraph disclaimer revised.

Chapter 3 – Informed Consent

- TOC (October 2012)
 - Revised to align with chapter page numbers.
- P. 2 (April 2012)
 - CIG reference updated.
- P. 11 (April 2015); p. 12 (April 2012) Appendix 3.1: Recommended Immunization Websites, Books and Articles for Parents and Caregivers
 - Revised fact sheet for parents
- P. 20 (April 2012) Appendix 3.3 Immunization Truths
 - Revised as per content in the current evergreen CIG

Chapter 5 Immunization Schedules

- P. 6 Section 1.5 Children 7 to 17 Years Who Present for Immunizations (February 2015)
 - **New** footnote: *** If the 3rd tetanus, diphtheria & pertussis containing dose was given before 4 years of age, the child requires another dose of Tdap to protect them until they are eligible (at 11 years old) for the adolescent Tdap dose in grade 8. They are considered up to date if 3rd dose was given ≥ 4 years of age.**
- P. 8 Section 1.7 Recommended Publicly Funded Immunizations for Adults Who Completed a Primary Childhood Vaccine Series (January 2015)
 - Pneu-P-23 reinforcement dose bullet amended as 5 years is recommended interval for all ages.

Chapter 7 Special Populations

- The following risk factors are ineligible to receive a 2-dose HPV series **and must receive** a 3-dose HPV series:
 - Acquire complement deficiency
 - Congenital immunodeficiency
 - HIV
 - Medical treatment
- The following conditions are “Eligible for only 1 publicly funded reinforcement dose 5 years after the first dose” regardless of age (≥2 years) that the first dose was received.
 - Asplenia – Congenital, Acquired or Functional
 - Liver Disease
 - Malignancies / Cancer
 - Renal Disease
 - Sickle Cell Disease
 - Congenital Immunodeficiency

Saskatchewan Immunization Manual Amendments **May 2015**

- Acquired Complement Deficiency
- Human Immunodeficiency Virus
- Medical Treatment

Chapter 10 Biological Products

- Hepatitis B Vaccine Series Completion Scenarios (May 2012)
 - The following has been added: Note: To ensure a consistent provincial approach, when a client's documented immunization record does not show the HB-containing vaccine volumes administered for previous doses in which a minimum 3-dose series has not been completed, it is recommended that:
 - 0.5 mL HB doses are administered to clients younger than 20 years of age at appropriate intervals to complete a 3-dose series.
 - 1 mL HB doses are administered to clients 20 years of age and older at appropriate intervals to complete a 3-dose series.
- Gardasil (April 2015)
 - Amendment to 2-dose schedule – applies to ages 11-14 years old, not 11-15 years old.
- Priorix-Tetra and ProQuad (both April 2015)
 - Bullet 3 corrected as symbol was incorrect, now reads: Grade 6 students who are ≤ 13 yrs, until they begin grade 7.
- Prevnar 13 page 1 of 2 (dated September 2014)
 - New PM link
- Pneumovax 23 (April 2015)
 - Lat bullet under Reinforcement now states: “hematopoietic stem cell transplant (HSCT) recipient (as per agency guidelines)”.
- HBIG (HepaGamB both pages and HyperHEP B S/D both pages)
 - Indication 3 removed, as dose/series associated with indication 3.
 - Footnote 4 – 2nd, 3rd and 4th sentences amended to align with CDC manual.